Liquid biopsy market seen reaching $27.34B by 2035

Market Research Future projects the global liquid biopsy market will grow from $10.06 billion in 2025 to $27.34 billion by 2035, fueled by rising cancer rates and demand for non-invasive diagnostics. The forecast points to strong momentum in oncology testing, sequencing technology, and AI-assisted clinical workflows.

Why it matters: - Liquid biopsy is gaining traction because it can support earlier cancer detection, treatment monitoring, and recurrence surveillance without invasive tissue sampling. - The market outlook reflects growing demand for faster, more patient-friendly diagnostics as cancer incidence rises worldwide. - Market Research Future projects the global market will expand at a 10.52% CAGR from 2025 to 2035.

What happened: - Market Research Future estimated the liquid biopsy market at $9.1 billion in 2024. - The firm projects the market will reach $10.06 billion in 2025 and $27.34 billion by 2035. - The forecast was published on Sept. 3, 2026. - The report links growth to rising cancer prevalence, improved sequencing and digital PCR tools, and greater use of artificial intelligence and machine learning in diagnostics. - The release included a request for a free sample, a customization request, and the full report.

The details: - The World Health Organization estimated 20.6 million new cancer cases in 2024 and projects 35 million annual cases by 2050. - WHO also estimates cancer causes nearly 10 million deaths a year. - Oncology was the largest application segment in 2024 with a 66% share. - Prenatal testing was identified as the fastest-growing application segment. - Blood was the largest sample type in 2024 with a 69% share. - Urine was identified as the fastest-growing sample type. - Next-generation sequencing held about 61% of market revenue in 2024. - Digital PCR is described as a fast-growing technology for measuring circulating tumor DNA. - Hospitals were the largest end-use segment in 2024 with a 58% share. - Diagnostic laboratories were identified as the fastest-growing end-use segment. - North America led the market in 2024 with more than 49.45% of global revenue, or about $4.5 billion. - Europe was valued at $2.73 billion in 2024 and held a 30% share. - Asia-Pacific was valued at $1.82 billion in 2024 and accounted for about 15% of global share. - The Middle East and Africa held about 5% of global share, valued at $0.1 billion in 2024.

Between the lines: - The report suggests liquid biopsy is moving from a niche oncology tool toward a broader diagnostic platform. - The strongest growth areas cluster around non-invasive cancer care, which fits the shift toward precision medicine and earlier intervention. - Competitive activity from Guardant Health, Exact Sciences, GRAIL, Roche Diagnostics, Illumina and others shows the market is still being shaped by clinical evidence, regulatory progress and product launches. - Exact Sciences launched Cancerguard commercially in 2025 at $689, while GRAIL said it sold more than 185,000 Galleri tests in 2025 and enrolled more than 174,000 participants across NHS-Galleri and PATHFINDER 2. - Guardant Health said its 2026 collaboration with Nuvalent supports companion-diagnostic development for targeted cancer therapies.

What's next: - Market Research Future expects new growth from early cancer detection platforms, multi-cancer screening tools and treatment-monitoring products. - Partnerships with healthcare providers are expected to expand integrated diagnostic and monitoring workflows. - The report also points to expansion in emerging markets as healthcare infrastructure and testing access improve. - By 2035, liquid biopsy is expected to be a more central part of cancer diagnostics.